Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CmlI is a non-heme diiron oxygenase that plays a critical role in the biosynthesis of the broad-spectrum antibiotic chloramphenicol in Streptomyces venezuelae [1, 2, 4]. It specifically catalyzes the final six-electron oxidation of the arylamine precursor, d-threo-1-(4-aminophenyl)-2-dichloroacetylamino-1,3-propanediol (NH2-CAM), to the arylnitro group found in the active antibiotic [1, 3, 5]. The enzyme's active site contains a (hydr)oxo- and carboxylate-bridged dinuclear iron cluster, which activates molecular oxygen to form a stable diferric-peroxo intermediate [1, 10, 41]. This intermediate facilitates the sequential oxygenation steps—converting the amine to a hydroxylamine, then to a nitroso group, and finally to the nitro group—without the dissociation of intermediates from the active site [3, 5, 48]. CmlI is a member of the heme oxygenase-like metalloenzyme (HDO) superfamily and is a subject of interest for its unique catalytic mechanism and potential applications in biocatalysis and the engineering of novel nitro-containing natural products [37, 39, 41]. The enzyme is notable for its ability to perform multiple oxidation steps within a single active site, preserving efficiency and specificity while avoiding the release of reactive intermediates [3, 5]. Structural studies have revealed a four-helix bundle fold that coordinates the diiron cluster, similar to other oxygen-activating enzymes like methane monooxygenase [2, 34, 38]. While not a direct therapeutic target in humans, CmlI and its homologs in pathogenic bacteria are studied for their roles in secondary metabolism and as potential targets for novel antimicrobial strategies [31, 35]. Its unique peroxo intermediate structure distinguishes it from other diiron enzymes, providing insights into the diverse ways nature activates oxygen for complex chemical transformations [41, 48].
Catalyzes the six-electron oxidation of an arylamine precursor to an arylnitro group via hydroxylamine and nitroso intermediates using a non-heme diiron cluster and molecular oxygen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-N-dichloroacetyl-p-aminophenylserinol N-oxygenase (CmlI) (CmlI).